Oridonin

DB19086InvestigationalSmall molecule

Oridonin is under investigation in clinical trial NCT05130892 (Effect of Inflammasome Inhibitor on Hscrp in Patients After PCI).

Mechanism: Pharmacologically active on Thioredoxin reductase 1, cytoplasmic, Exportin-1, and NACHT, LRR and PYD domains-containing protein 3
Curator reviewed
Formula / weight: C₂₀H₂₈O₆ · 364.438 g/mol (avg)
Also known as: Isodonol · Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1.alpha.,6.beta.,7.alpha.,14r)- · Kaur-16-en-15-one, 7.alpha.,20-epoxy-1.alpha.,6.beta.,7,14-tetrahydroxy-, (14r)- · Oridonine · Pure oridonin
Code names: NSC-250682

Resolves to

Compound

UNII0APJ98UCLQCAS28957-04-2ChEMBLCHEMBL1164920ChEBI138236

Structure

InChIKeySDHTXBWLVGWJFT-XKCURVIJSA-NSMILES[H][C@@]12CC[C@]3([H])[C@@]([C@@H]1O)(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O

Targets

Q16881TXNRD1O14980XPO1Q96P20NLRP3P19338NCL

What you can answer from here — as of July 09, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oridonin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account